ENTEROME is a technology company.
ENTEROME has raised $148.0M across 7 funding rounds.
ENTEROME has raised $148.0M in total across 7 funding rounds.
ENTEROME has raised $148.0M in total across 7 funding rounds.
ENTEROME's investors include Edward Van Wezel, Forbion, Novartis Venture Fund, Seventure Partners.
Enterome is a clinical-stage biotechnology company specializing in the development and commercialization of novel therapies and diagnostics targeting disorders linked to disruptions in the intestinal microbiota. Its primary focus is on chronic inflammatory bowel diseases (IBD), various cancers, and immune-related diseases. Enterome leverages proprietary quantitative and functional metagenomics platforms to discover therapeutic targets and biomarkers, serving pharmaceutical partners and ultimately patients with unmet medical needs in microbiome-related conditions. The company has demonstrated strong growth momentum through significant funding (€63.8 million raised), multiple patents, and strategic collaborations with major pharmaceutical firms such as Bristol-Myers Squibb, Johnson & Johnson, Takeda, and AbbVie[1][2][3].
Founded from scientific breakthroughs at the French National Institute for Agricultural Research (INRA), Enterome emerged to translate advanced microbiome research into therapeutic innovations. The company was established by scientists with deep expertise in metagenomics and microbiota biology, aiming to harness the gut microbiome’s role in disease. Early traction came from pioneering quantitative metagenomics technologies and securing partnerships with leading pharmaceutical companies, which validated its platform and accelerated clinical development programs. These collaborations, including a notable 2016 immuno-oncology partnership with Bristol-Myers Squibb, have been pivotal in advancing Enterome’s pipeline and industry standing[1][2].
Enterome operates at the intersection of microbiome science, immuno-oncology, and personalized medicine—a rapidly growing and transformative sector in biotech. The timing is critical as scientific consensus increasingly recognizes the gut microbiome’s influence on immune response, cancer progression, and chronic inflammation. Market forces such as rising prevalence of immune and inflammatory diseases, advances in metagenomic technologies, and pharmaceutical interest in microbiome-targeted therapies create a favorable environment. Enterome’s work not only advances therapeutic options but also helps set industry standards for microbiome analysis, influencing research and drug development ecosystems globally[1][2].
Looking ahead, Enterome is poised to expand its clinical pipeline and deepen collaborations with pharmaceutical leaders, potentially bringing first-in-class microbiome-based therapies to market. Trends shaping its journey include the growing integration of microbiome data in precision medicine, advances in immunotherapy, and increasing regulatory acceptance of microbiome diagnostics. As Enterome matures, its influence may extend beyond drug development to shaping microbiome research standards and fostering new therapeutic paradigms. This positions Enterome as a key innovator driving the future of microbiome-related healthcare solutions[1][2][3].
ENTEROME has raised $148.0M across 7 funding rounds. Most recently, it raised $19.0M Venture Round in June 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2025 | $19.0M Venture Round | Edward Van Wezel, Forbion, Novartis Venture Fund, Seventure Partners | |
| Jun 1, 2020 | $52.0M Series E | Edward Van Wezel, Forbion, Novartis Venture Fund, Seventure Partners | |
| Dec 1, 2016 | $34.0M Series D | Edward Van Wezel, Forbion, Novartis Venture Fund, Seventure Partners | |
| Apr 1, 2016 | $16.0M Series C | Edward Van Wezel, Forbion, Novartis Venture Fund, Seventure Partners | |
| Apr 1, 2014 | $15.0M Series B | Edward Van Wezel, Forbion, Novartis Venture Fund, Seventure Partners | |
| Mar 1, 2012 | $10.0M Series A | Edward Van Wezel, Forbion, Novartis Venture Fund, Seventure Partners | |
| Dec 1, 2010 | $2.0M Seed | Edward Van Wezel, Forbion, Novartis Venture Fund, Seventure Partners |